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Abstract
Background: The aim of this study is to use a systematic review framework to identify and synthesise the evidence
on the use of proton beam therapy (PBT) for the treatment of children with CNS tumours and where possible
compare this to the use of photon radiotherapy (RT).
Methods: Standard systematic review methods aimed at minimising bias will be employed for study identification,
selection and data extraction. Twelve electronic databases have been searched, and further citation, hand searching
and reference checking will be employed. Studies assessing the effects of PBT used either alone or as part of a
multimodality treatment regimen in children with CNS tumours will be included. Relevant economic evaluations
will also be identified. The outcomes are survival (overall, progression-free, event-free, disease-free), local and
regional control rates, short- and long-term adverse events, functional status measures and quality of survival. Two
reviewers will independently screen and select studies for inclusion in the review. All interventional study designs
will be eligible for inclusion in the review. However, initial scoping searches indicate the evidence base is likely to
be limited to case series studies, with no studies of a higher quality being identified. Quality assessment will be
undertaken using pre-specified criteria and tailored to study design if applicable. Studies will be combined using a
narrative synthesis, with differences in results between studies highlighted and discussed in relation to the patient
population, intervention and study quality. Where appropriate, if no studies of a comparative design are identified,
outcomes will be compared against a range of estimates from the literature for similar populations and treatment
regimens from the best available evidence from studies that include the use of advanced conventional photon therapy.
Discussion: The evidence base for the use of PBT in children with CNS tumours is likely to be relatively sparse, highly
heterogeneous and potentially of a low quality with small sample sizes. Furthermore, selection and publication biases
may limit the internal and external validity of studies. However, any tentative results from the review on potential
treatment effects can be used to plan better quality research studies that are of a design appropriate for outcome
comparison with conventional therapy.
Systematic review registration: PROSPERO CRD42015029583
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Background
Tumours of the central nervous system (CNS) represent a
group of neoplasms that account for approximately 25 %
of all childhood cancers. These tumours are both anatom-
ically and histologically diverse. They are the leading cause
of cancer-related death in childhood, and whilst it has be-
come clear that the use of multimodal treatment regimens
including surgery, radiotherapy (RT) and chemotherapy
can increase survival, 60 % of survivors are moderately or
severely disabled due to the disease and treatment-related
effects [1]. With more individuals having the prospect of
long-term survival, the focus of treatment has therefore
started to shift from one of ‘cure at all costs’ to ‘the cost of
cure’. Novel treatment strategies are therefore being intro-
duced in an attempt to maintain or increase survival rates
whilst maximising the quality of the resultant long-term
survival. Proton beam therapy (PBT) is one such treat-
ment approach.
Conventional photon RT used primarily as a local therapy
aims to provide improved local tumour control and cure
whilst minimising radiation doses to adjacent normal tis-
sues. However, the appropriate targeting and delivery of ra-
diation dose is complex and is particularly difficult for
tumours adjacent to radiation-sensitive critical body struc-
tures (the so-called organs at risk) such as the pituitary,
optic chiasm, hippocampus, lungs, bowel, ovaries, heart and
thyroid gland. For this reason, in clinical practice, tumour
lethal doses are not always achieved due to the need to bal-
ance the desired damage to the tumour with the undesirable
radiation-induced injury to adjacent healthy tissues [2]. This
is generally achieved by targeting the beam to the tumour
area through paths that spare nearby critical and radiosensi-
tive anatomical structures, selecting multiple fields that
cross in the tumour area through different paths, and split-
ting the total dose into multiple smaller dose ‘fractions’ that
are delivered over several days to weeks, thereby allowing
damage to normal tissues to recover between treatments.
PBT is a form of RT that delivers radiation within a
defined radiation track length, with virtually no dose be-
yond the intended target [3]. In contrast to conventional
RT, where potentially larger volumes of healthy tissue
are irradiated, PBT is associated with smaller normal
tissue-irradiated volumes [4–8], decreasing the dose to
healthy tissues by a factor of 1.5 to 3.0 mainly due to the
generally lower entrance dose and the complete elimin-
ation of exit dose compared to photon beams [9].
It therefore allows the benefit of a more localised delivery
of RT that can be exploited either by targeting higher RT
doses to the tumour without increased RT-induced normal
tissue toxicity or by reducing adverse effects at equally ef-
fective doses. At the present time, most PBT is delivered
using three-dimensional conformal techniques (3D-CPT)
via the passive beam scattering method. However, proton
pencil beam scanning (PBS) techniques are gradually being
introduced at several institutions [10], with these allowing
for delivery of intensity-modulated proton therapy (IMPT)
and the potential to further improve the target conformity
and sparing of adjacent healthy organs.
The use of PBT in the treatment of children with CNS
tumours is particularly appealing given the fact that some
tumours may not be surgically operable, the radiosensitiv-
ity of the brain and spinal cord, and the need to minimise
the deleterious effects of RT on the developing CNS. Sec-
ondary malignancies and late effects of treatment are of
particular concern in long-term survivors of childhood
CNS tumours following conventional RT, and results of
dose planning studies have raised the question as to
whether the improved dose distribution in proton therapy
may reduce the risk of secondary malignancies [7, 8].
To date, a number of case series studies have assessed
the effectiveness, safety or long-term treatment sequelae of
the use of proton RT in children with different malignant
CNS tumours. These have included children with low-
grade gliomas (LGG) [11, 12], ependymoma [13], germ cell
tumours [14], pineoblastoma [15] and atypical teratoid/
rhabdoid tumours (AT/RT) [16]. Whilst three systematic
reviews have previously been conducted on the use of PBT,
these have included both children and adults with all types
of cancer diagnoses and were published in 2007 [17, 18]
and 2009 [19]. They therefore do not provide a compre-
hensive up-to-date assessment of the use of PBT in the
treatment of children with CNS tumours. Additionally, two
recent non-systematic literature reviews highlighting
further studies on the effects of PBT in the treatment
of children with CNS tumours have now been under-
taken [20, 21], and therefore, there is a need to pro-
vide a systematic up-to-date review of the evidence
relating to the use of this technology in children with
CNS tumours.
However, all of these reviews highlight the lack of the
evidence for comparing the effects of PBT with conven-
tional or advanced photon RT [17–21], with nearly all
the evidence based on small, single-group, retrospective
case series studies. It is acknowledged within the present
proposed review that this is not an appropriate design for
comparing the relative effects of PBT and conventional
RT, and therefore, the aim of the review is to use a trans-
parent, replicable systematic review framework based on
the ‘best-evidence’ approach [22, 23] in order to identify
and synthesise the available evidence on the impact of
treatment with PBT in children with CNS tumours.
Methods
Standard systematic review methodology aimed at minimis-
ing bias will be employed, and reporting will follow the Pre-
ferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines [24]. The protocol for this
review is registered with PROSPERO (CRD42015029583),
Main et al. Systematic Reviews  (2016) 5:124 Page 2 of 7
available from http://www.crd.york.ac.uk/PROSPERO/
display_record.asp?ID=CRD42015029583. The Preferred
Reporting Items for Systematic Review and Meta-
Analysis Protocols (PRISMA-P) checklist for the re-
view is also included as Additional file 1.
Data sources and searches
This review forms part of a wider work programme of sys-
tematic reviews that aim to assess the effects of different
interventions for the treatment of CNS tumours in chil-
dren, adolescents and young adults. Searches have there-
fore been conducted for studies examining the effects of
surgery, radiotherapy, chemotherapy, immunotherapy, hor-
mone therapy, biological therapies and imaging used alone
or as part of a multimodality treatment regimen for all
types of paediatric brain tumours. No study design filters
have been applied to the searches. Specific details of the
searches conducted are detailed below.
Bibliographic databases A comprehensive, broad search
strategy was developed using a combination of Medical
Subject Headings (MeSH) and free-text terms. The searches
were limited by date from 1985 to November week 1, 2014,
and updated in November week 1, 2015. No language or
publication status restrictions were applied, and ongoing
studies were included.
The searches for published studies were undertaken
using the following databases: MEDLINE (OvidSP); MED-
LINE In-Process Citations and Daily Update (OvidSP);
EMBASE (OvidSP); Cochrane Database of Systematic
Reviews (CDSR) (Wiley); Cochrane Central Register of Con-
trolled Trials (CENTRAL) (Wiley); CINAHL Plus (EBSCO);
PsycINFO (OvidSP); NHS Economic Evaluation Database
(NHS EED) (CRD website), DARE (CRD website); and HTA
(CRD website). The search strategy used for the MEDLINE
search is reported in the Appendix.
Grey literature Completed and ongoing studies were
identified by searches of NIH Clinical Trials (http://
www.clinicaltrials.gov/); Current Controlled Trials (http://
www.controlled-trials.com/); and WHO International Clin-
ical Trials Registry Platform (ICTRP) (http://www.who.int/
ictrp/en/).
Other sources Experts in the field, from both the Pro-
ject Advisory and Patient and Public Involvement (PPI)
Groups, were contacted with a list of identified studies
to find out whether they had knowledge of any further
studies that had not been retrieved by the electronic
searches. Reference lists of all studies included in the
present review will be checked, citation searching will be
undertaken and the following books of conference ab-
stracts will be hand-searched:
Annual Meeting of the American Society for Radiation
Oncology (ASTRO) (56th and 57th meeting abstracts)
International Society of Paediatric Oncology (SIOP)
(46th and 47th meeting abstracts)
International Symposium on Pediatric Neuro-Oncology
(ISPNO) (15th and 16th meeting abstracts)
American Society of Clinical Oncology (ASCO) (2014
and 2015)
All identified references have been downloaded into End-
note X7 software for initial assessment and handling. Where
flexibility is needed throughout the work programme for
reference management and handling, Endnote software will
be linked to bespoke Access databases in order to facilitate
sorting and manipulation of data items within indexed fields
and abstracts. As a preliminary first stage to the broader set
of reviews, and as an aid to the research question prioritisa-
tion process, inclusion screening on the basis of population
and the broader set of applicable interventions has already
been undertaken, with all included studies being ‘mapped’
by study design.
Study selection
All studies have been loosely ‘tagged’ according to the study
design and type of intervention using the seven interven-
tion categories outlined above. All studies ‘tagged’ as proton
therapy will be used to form the potential pool from which
studies will be screened against the specific inclusion cri-
teria. Study selection will be undertaken by two reviewers
working independently initially using the titles/abstracts
from the pool of potential studies. Studies marked for inclu-
sion by either reviewer will then undergo full independent
text assessment. Any discrepancies will be resolved by re-
course to the abstracts or full texts or through consensus
with a third reviewer. A PRISMA flow chart illustrating the
study selection process will be documented [24].
Inclusion/exclusion criteria
Population The study population covers infants, chil-
dren and young adults (up to approximately age 25 years)
with diagnoses of any type of malignant CNS tumour.
These include but are not limited to high- and low-
grade gliomas (HGG and LGG), diffuse intrinsic pontine
glioma (DIPG), medulloblastoma, ependymoma, germ
cell tumours, atypical teratoid/rhabdoid tumour (AT/
RT), primitive neuroectodermal tumours (PNET) and
pineoblastoma. Studies that include both children and
adults within the relevant populations or that include chil-
dren with different types of CNS tumours will be included
provided that participant baseline demographic data and
outcomes are reported separately for children by CNS
tumour type.
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Interventions Interventions include PBT used either
alone or as part of a multimodality treatment regimen
that may include conventional photon external beam
radiation.
Comparator (for controlled studies) The comparator
used in this study is conventional photon external beam
radiation including 3D conformal techniques or intensity-
modulated radiotherapy (IMRT) including arc therapy,
stereotactic radiosurgery or brachytherapy used alone or
as part of a multimodality treatment programme. Data on
the range of outcome estimates for use of the most
advanced types of photon radiation in each tumour type
included in the review will be sought (if necessary) in
order to allow an informal comparison with the outcome
estimates from studies included in the review if no
controlled studies of PBT are identified.
Outcomes The outcomes are overall survival (OS),
surrogate survival outcomes (progression-free (PFS),
disease-free (DFS), event-free (EFS)), local control, regional
control, short- and long-term adverse events, functional
status measures (including neurocognitive and educational
outcomes) and quality of survival. Studies that only report
changes on magnetic resonance images (MRI) or evaluate
treatment planning or dosimetry without providing any
data on clinical outcomes or adverse events will be
excluded.
Study designs The study designs include randomised
controlled trials (RCTs), non-randomised trials, phase II
single-arm trials, prospective and retrospective case
series and ongoing trials. Relevant economic evaluations
will also be identified. Cross-sectional studies and mul-
tiple and single case reports will be excluded.
Data extraction
Data will be recorded on a standard data extraction form
developed in either Access or Excel. The data will be ex-
tracted by one reviewer and checked by a second for ac-
curacy. Any discrepancies will be resolved by recourse to
the paper. Data from studies with multiple publications
will be extracted and reported as a single study.
Data will be extracted on the following: general informa-
tion (study name, study group (if applicable), publication
date(s), principal investigator/authors); patient eligibility
and study participants (e.g. tumour type and location,
grade, age, gender, prior treatment history); RT image plan-
ning (e.g. computerised tomography (CT) or MRI, imaging
plane and weighting, image contrast enhancement); defin-
ition of clinical tumour volume and margins; intervention
and comparator (where applicable): RT (type, dosimetry
(Gy), fractions, field arrangement and number of fields,
concomitant therapy), number of administrations and time
frame, any supportive care, treatment intent (radical or pal-
liative), study design (e.g. controlled trial, single-arm phase
II trial or case series), length of follow-up and timing of
outcome assessments; outcome measures (protocol speci-
fied—if available—and reported); side effects/toxicity, long-
term adverse events and neuropsychological outcomes;
analysis methods (ITT or per protocol); and the author’s
conclusions. If any controlled studies are identified, out-
comes will be recorded separately for controlled and obser-
vational studies.
Assessment of risk of bias in studies
If there are any RCTs identified, study quality will be
assessed using the Cochrane Risk of Bias tool [25]. It is,
however, anticipated that the research evidence will be
non-comparative in nature; therefore, to assess the risk of
bias, the checklist adapted by Wilson and colleagues [26]
based upon the six-point checklist developed by CRD,
York, for the assessment of observational studies will be
used (http://www.york.ac.uk/crd/SysRev/!SSL!/WebHelp/
SysRev3.htm) [27]. This covers the domains of selection,
detection and attrition bias. Additional criteria will also be
used to assess the adequacy of the sample size and methods
of analyses, whether all assessed outcomes are reported,
and the likely external validity of the study. All assessments
will be at the overall study level, not at the level of the indi-
vidual outcomes. Quality assessment will be undertaken by
one reviewer and independently checked for accuracy by a
second. Any disagreements will be resolved by recourse to
the study paper(s), and a third reviewer will be consulted
where necessary.
Data synthesis and analysis
A narrative synthesis of study results will be presented (in-
cluding text, figures and tables), to provide adequate inter-
pretation of study findings. The initial narrative syntheses
from the review team will be developed, discussed, refined
and tested iteratively with clinical members of the team until
a final consensus or conclusion is reached. Where appropri-
ate, the summary figure for outcomes will be expressed as a
weighted mean (weighted by the initial sample size). Studies
will be grouped by tumour type, by treatment line (induc-
tion, consolidation, salvage) and then by the intervention
(where this differs significantly between studies). Differences
between the studies will be highlighted and discussed in re-
lation to the patient population, intervention and study
quality. Where appropriate (and no comparative studies are
identified), outcomes for studies will be compared against a
range of estimates from the literature for similar populations
and treatment regimens that include the use of the most
relevant and up-to-date advanced conventional photon ther-
apy as part of the multimodal treatment regimen to provide
a context for the interpretation of results.
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Where more than one RCT has addressed the same
question and they are considered to be clinically similar
(based on patient population and study treatments), re-
sults will be combined in a standard pairwise meta-
analysis using assumption-free methods. All analyses will
be carried out on an intention-to-treat (ITT) basis where
possible, using the HR or RR as appropriate. Heterogen-
eity of treatment effect, if present, will be investigated
using the chi-squared test for heterogeneity and the I2
statistic [28]. Further sub-group analyses, to explore dif-
ferences between the trials in terms of patient baseline
characteristics such as tumour grade and prior treat-
ments (dose, number of cycles), will be undertaken as
necessary to investigate whether the treatment effect dif-
fers between patient sub-groups.
An overview of the results and the range of costs of
any up-to-date, robust economic evaluations and the
limitations of the existing models will be presented in
the ‘Discussion’ section.
Discussion
Although this methodology has been designed to be com-
prehensive and to minimise bias, any results are likely to
be highly tentative and context specific. The evidence base
is likely to be sparse, highly heterogeneous and of a low
quality with small sample sizes. Furthermore, the included
studies are likely to be subject to selection bias, as PBT is
only conducted at a limited number of highly specialised
centres. Furthermore, access to PBT especially within the
USA is linked to insurance status, and the treatment of
patients with different clinical indications may potentially
be associated with whether PBT facilities are run on a for-
profit or non-profit basis. This means that the external
validity of the studies is likely to be low, with patients en-
tered into the studies differing from those that might gen-
erally be seen in practice. It is therefore posited that the
‘noise’ to ‘signal’ ratio within the data will be high, and it
will be difficult to delineate any potential treatment ef-
fects. Moreover, there is strong potential for significant
publication bias within the review due to the poor index-
ing of case series studies, and the lack of any requirement,
or indeed web-based portal on which to register non-
comparative studies. There will therefore be a strong reli-
ance on identifying potentially relevant literature through
‘snowballing’ techniques, reference checking, citation
searching and contact with experts in the field to identify
studies that have only recently been completed. However,
given the impact of the introduction of PBT within the
UK by 2018 with significant financial resources being
invested in facilities, and the impact that this might have
for the treatment of children with CNS tumours, it is im-
portant to undertake this review despite the potential
methodological limitations and caveats outlined above.
Moreover, the assembly of evidence on the potential
impact of different treatment settings and across different
sub-populations can be used to make informed decisions
regarding the likely impact of the implementation of the
technology within new settings and be used to plan better
quality research studies that are appropriate for outcome
comparison with advanced conventional therapy.
To ensure that our findings have clinical impact on pa-
tients, their parents and the physicians who care for them,
results will be disseminated broadly by presenting at sci-
entific conferences, publishing in peer-reviewed journals
and through our established PPI Partners who are associ-
ated with high-profile brain tumour charities.
Appendix
Clinical Effectiveness Search Strategy
Medline (OvidSP): 1985- October Week 4 2014
1. Glioma/or Brain Neoplasms/or Meningioma/or
Glioblastoma/or Astrocytoma/
2. ((brain or brainstem or intracranial or posterior fossa)
adj3 (cancer* or carcinom* or tumor* or tumour* or
neoplasm*)).mp.
3. (Astrocytoma* or Brain Stem Glioma* or Medullobl
astoma*or Primitive Neuroectodermal Tumo?r* or
ganglioneuroblastoma* or CNS neuroblastoma* or
Ependymoblastoma or Medulloepithelioma or Pineal
Parenchymal Tumour* or (Atypical Teratoid adj1
tumo?r*) or Oligoastrocytoma or ((Pilocytic or
Gemistocytic) adj1 astrocytoma*) or ependymoma or
primitive neuroectal tumo?r*).mp.
4. (((Diffuse fibrillary or Gemistocytic or Pilocytic Pilo
myxoid Protoplasmic Subependymal giant cell) adj1
astrocytoma*) or Oligoastrocytoma or Oligodendr
oglioma or Oligoastrocytoma or Pleomorphic
xanthoastrocytoma or ((astrocytoma or oligoastro
cytoma or oligodendroglioma) adj1 astrocytoma*)
or Glioblastoma or Gliomatosis cerebri or Glios
arcoma or ((diffuse intrinsic pontine glioma or low
grade brain stem) adj1 glioma) or ((classic or
desmoplastic or nodular or large cell or nodularity)
adj1 medulloblastoma*) or Primitive Neuroectoder
mal Tumo?r* or ((ganglioneuroblastoma or neurobla
stoma) adj 1central nervous system*) or Ependymo
blastoma or Pineoblastoma or pineal parenchymal
tumo?r* or (central nervous system adj1 atypical
teratoid) or (central nervous system adj 1 rhabdoid
tumo?r*) or Germinomas or ((immature or mature
or malignant transformation) adj2 teratomas)).mp.
5. 1 or 2 or 3 or 4
6. exp Surgical Procedures, Operative/
7. surg*.mp.
8. debulk*.mp.
9. cytoreduc*.mp.
10. 6 or 7 or 8 or 9
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11. (chemotherap* or antineoplastic agents or cytotoxic
or alkylating agents or nitrosoureas or antimetabolite*
or antitumor?r or ((antibod* or monoclonal) adj 3
Human*) or plant alkyloid* or (hormone* adj 1
agent*) or anthracycline* * or systemic therap*).mp.
12. (Everolimus or Afinitor or Cetuximab or Erbitux
or Bevacizumab or Avastin or Cediranib or Recentin
or lomustine or CCNU or CeeNU or carmustine
or BiCNU or Carustine or Ethylnitrosourea or
Streptozocin or Sorafenib or Nexavar or tipifarnib or
Zarnestra or Erlotinib or Tarceva or Sorafenib
or Nexavar or temsirolimus or Torisel or Sunitinib or
Sutent or irinotecan or Camptosar or Campto or
Vandetanib or Caprelsa or Cabozantinib or Cometriq
or XL184 or Axitinib or AG013736 or Inlyta).mp.
13. 11 or 12
14. exp Immunotherapy/ae, cl, ct, mt, mo, nu, px, st
15. exp Genetic Therapy/ae, cl, ct, mt, mo, nu, ut
16. exp Imaging, Three-Dimensional/or exp Whole Body
Imaging/or exp Magnetic Resonance Imaging/
17. exp Tomography, Emission-Computed/or exp Four-
Dimensional Computed Tomography/or exp To
mography/or exp Tomography, Emission-Compu
ted, Single-Photon/or exp Positron-Emission
Tomography/
18. 16 or 17
19. (radiation therapy or radiotherap* or intensity modul
at* radiotherapy*or radiosurgery or radiation
oncology or reduced boost volume radiotherap* or
hyper fractionat* stereotactic radiotherap*or adjuvant
radiotherap* or body radiotherap* stereotactic*or
computer assisted radiotherap*or computer assisted
radiotherap*planning or conformal radiotherap*
or dosage* radiotherap* or dose fractionation*
radiotherap* or high energy radiotherap*or implant
radiotherap*or intensity or modulated radiotherap*or
interstitial radiotherap*orimage guided radiotherap*or
stereotactic*guid* radiotherap* or local therap*
or proton therap* or proton adj2 therap* or
proton beam therap* or proton adj2 radiation or
proton radiation therap* or proton adj2 radiotherap*
or proton adj2 irradia* or PBT).mp.
20. 10 or 13 or 14 or 15 or 18 or 19
21. 5 and 20
22. (Response or overall survival or progression* free
survival or event* free survival or time to recurrence
or time to progression or disease* free interval* or
endocrinopath* or ((growth or thyroid) adj 1 hormone
adj 3 deficienc*) or ((glucocorticoid or gonadotropin)
adj 3 deficienc*) or endocrine dysfuct* or (cardiac
function* adj 3 impair*) or ataxia or spastic paresis or
visual dysfunction or epilepsy or hemiparesis or
neurolog* deficit*).mp.
23. 21 and 22
24. limit 23 to (yr = “1985 -Current” and (“newborn infant
(birth to 1 month)” or “infant (1 to 23 months)” or
“preschool child (2 to 5 years)” or “child (6 to
12 years)” or “adolescent (13 to 18 years)” or
“young adult (19 to 24 years)”) and humans)
Additional file
Additional file 1: Preferred Reporting Items for Systematic Reviews and
Meta-Analysis Protocols (PRISMA-P) 2015 checklist for the effectiveness
and safety of proton beam radiation therapy in children with malignant
central nervous system (CNS) tumours.
Abbreviations
AT/RT, atypical teratoid/rhabdoid tumour—an embryonal tumour that can
occur anywhere in the central nervous system; CNS, central nervous system—the
part of the nervous system consisting of the brain and the spinal cord;
CT, computerised tomography—radiography in which a three-dimensional
image of a body structure is constructed by computer from a series of plane
cross-sectional images made along an axis; Gy, the gray—a derived unit
of ionising radiation dose defined as the absorption of 1 J of radiation
energy per 1 kg of matter; IMRT, intensity-modulated radiotherapy—an
advanced high-precision type of radiotherapy that uses computer-controlled
linear accelerators to deliver precise radiation doses that conform to the shape of
a tumour or specific area within a tumour; LGG, low-grade gliomas—tumours
that exhibit glial differentiation and lack high-grade findings such as microvascular
proliferation and necrosis; MRI, magnetic resonance imaging—a technique that
uses a magnetic field and radio waves to create detailed images of the organs
and tissues within the body; PBS, proton pencil beam scanning—a type of proton
beam therapy in which a lot of small pencil beams are directed into the target in
order to cover the 3D volume; PBT, proton beam therapy—a type of radiotherapy
that uses proton beams as opposed to standard photon radiotherapy that uses
X-ray beams composed of primary photons and secondary electrons
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